Skin cancer and immunosuppression.
7 (14%) out of 51 kidney-allograft recipients developed a total of 19 malignant skin tumours four to forty-five months after transplantation. Immunosuppressive treatment, known to be associated with an increased risk of development of tumours of lymphoreticular type, also enhances the occurrence of squamous-cell carcinoma. Under the influence of immunosuppression cutaneous hyperkeratoses more rapidly evolve into squamous-cell carcinoma, multiple skin cancers occur in some patients, and keratoacanthoma is not only more frequent but also prone to early recurrence.
D000328:Adult; D001379:Azathioprine / Q000009:adverse effects; D002280:Basal Cell Carcinoma / Q000139:chemically induced*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007636:Keratoacanthoma / Q000139:chemically induced*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects; D012306:Risk; D012871:Skin Diseases / Q000139:chemically induced*; D012878:Skin Neoplasms / Q000139:chemically induced*
D007166:Immunosuppressive Agents; D001379:Azathioprine; D011241:Prednisone